荃信生物-B(02509)发布公告，于2025年11月17日，该公司斥资71.19万港元回购3.46万股股份，每股回 购价格为20.16-20.72港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇荃信生物醫藥股份有限公司 呈交日期： 2025年11月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包 ...

Group 1 - Tsugami Machine Tool China (01651) saw a rise of over 5.4% due to increased demand for high-precision machine tools in emerging sectors like new energy vehicles and artificial intelligence as China's economy gradually recovers [1] - Black Sesame Intelligence (02533) increased by over 2.2% after announcing that its flagship product, the Huashan A1000 automotive-grade high-performance driving assistance chip, has been successfully integrated into Desay SV's new low-speed unmanned vehicle brand "Chuanxing Zhiyuan" S6 series [1] - Zai Xin Bio-B (02509) rose over 5.8% after receiving clinical trial approval for its self-developed long-acting dual antibody QX027N injection, intended for the treatment of asthma and atopic dermatitis [1] - CanSino Biologics (06185) increased nearly 5% as it announced the initiation of Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia [1] Group 2 - Kingsray Biotechnology (01548) rebounded over 4.48% following the financial performance disclosure of its joint venture Legend Biotech for the third quarter ending September 30, 2025 [2] - Fuhong Hanlin (02696) rose over 5.2% after its PD-1 antibody drug, Surufilumab injection, was proposed for breakthrough therapy designation for use in combination with chemotherapy for gastric cancer [2] - Yidu International Holdings (00259) increased over 6% amid uncertainty regarding the impact of an undisclosed event on its financial statements for the year ending March 31, 2025 [2] Group 3 - Reshaping Energy (02570) surged nearly 60%, with a rise of 55.03%, following announcements from the National Energy Administration encouraging the use of green hydrogen in coal chemical projects and plans to promote over 2,000 hydrogen vehicles in Shandong Province [3] - Laika Pharmaceuticals-B (02105) saw a reverse increase of over 10.3% after granting Qilu Pharmaceutical exclusive rights for research, development, and commercialization of the breast cancer candidate drug LAE002 (afuresertib) in China [3] Group 4 - WMCH GLOBAL (08208) resumed trading with a rise of over 50%, increasing by 57.45% after announcing the sale of approximately 384 million shares, representing about 53.297% of its issued share capital [4] Group 5 - U.S. stock market opened lower, with the Nasdaq dropping 2.04%, as major tech stocks like Nvidia, AMD, and Tesla saw declines [5] - Tencent reached an agreement with Apple regarding payment processing for WeChat mini-games, potentially opening new revenue streams for Apple [5] - Mangoceuticals (MGRX.US) plummeted 32.39% after announcing partnerships with Eli Lilly and Novo Nordisk to provide users with weight loss medications [6] - Fannie Mae (FNMA.US) fell 9.82%, with a two-day cumulative drop of 20%, amid investigations into the actions of the Federal Housing Finance Agency director [6] - Disney (DIS.US) dropped 7.75% despite strong performance in streaming and theme parks, as upcoming major film releases are expected to impact first-quarter performance [6]

Core Viewpoint - 荃信生物-B (02509.HK) experienced a significant increase in stock price, rising over 8% in early trading, indicating positive market sentiment towards the company [2] Group 1 - The stock price of 荃信生物-B reached 22.08 HKD, reflecting an increase of 8.45% [2] - The trading volume amounted to 560.3 million HKD, suggesting active investor interest [2]

Core Viewpoint - The company, Qianxin Biopharmaceuticals-B (02509), has seen its stock price rise over 8% following the announcement of clinical trial approval for its long-acting dual antibody QX027N, aimed at treating asthma and atopic dermatitis [1] Group 1: Clinical Developments - Qianxin Biopharmaceuticals has received implied clinical trial approval from the National Medical Products Administration for its self-developed long-acting dual antibody QX027N [1] - The clinical approval marks the entry of the company's innovative dual antibody matrix into the clinical stage for autoimmune and allergic diseases [1] Group 2: Strategic Partnerships - On October 28, Qianxin Biopharmaceuticals announced a global exclusive collaboration and licensing agreement with Roche for its self-developed long-acting autoimmune dual antibody QX031N [1] - Under the agreement, Roche will have exclusive rights for research, development, registration, production, and commercialization of QX031N globally [1] - Qianxin Biopharmaceuticals will receive an upfront payment of $75 million, with potential milestone payments of up to $995 million and tiered royalties on future product sales [1]

Core Viewpoint - The stock of Zai Lab Limited (荃信生物-B) surged over 8% following the announcement of its long-acting dual antibody QX027N receiving clinical trial approval from the National Medical Products Administration, marking a significant advancement in the company's innovation pipeline for autoimmune and allergic diseases [1] Group 1: Clinical Developments - Zai Lab's QX027N injection is intended for the treatment of asthma and atopic dermatitis, indicating the company's commitment to addressing unmet medical needs in these areas [1] - The clinical trial approval signifies the official entry of the company's innovative dual antibody matrix into the clinical stage [1] Group 2: Strategic Partnerships - On October 28, Zai Lab announced a global exclusive collaboration and licensing agreement with Roche for its long-acting autoimmune dual antibody QX031N [1] - Under the agreement, Roche will gain exclusive rights for research, development, registration, production, and commercialization of QX031N globally [1] - Zai Lab will receive an upfront payment of $75 million, with potential milestone payments of up to $995 million, along with tiered royalties on future product sales [1]

Core Viewpoint - The stock of Zai Lab Limited (02509) rose over 8% following the announcement of clinical trial approval for its self-developed long-acting dual antibody QX027N, aimed at treating asthma and atopic dermatitis [1] Group 1: Clinical Developments - Zai Lab's long-acting dual antibody QX027N injection received implied clinical trial approval from the National Medical Products Administration, marking a significant step into clinical stages for the company's innovative dual antibody matrix in autoimmune and allergic diseases [1] - The company also announced a global exclusive collaboration and licensing agreement with Roche for its self-developed long-acting autoimmune dual antibody QX031N, granting Roche rights for research, development, registration, production, and commercialization [1] Group 2: Financial Aspects - Under the agreement with Roche, Zai Lab will receive an upfront payment of $75 million, with potential milestone payments of up to $995 million, along with tiered royalties on future product sales [1]

Core Viewpoint - The company has received clinical trial approval for its long-acting bispecific antibody QX027N, which is intended for the treatment of asthma and atopic dermatitis, marking a significant advancement in its innovative dual antibody matrix in the field of autoimmune and allergic diseases [1] Group 1 - The clinical trial approval was granted by the National Medical Products Administration, with acceptance numbers CXSL2500757 and CXSL2500758 [1] - QX027N represents an important achievement in the company's bispecific antibody research and signifies further progress in its strategic layout for respiratory and skin diseases [1] - The company aims to address the clinical needs of millions of asthma and atopic dermatitis patients globally by continuing to advance innovative therapies for more effective, safer, and more convenient treatment options [1]

Core Viewpoint - The company, Qianxin Biologics-B (02509), has received clinical trial implicit approval from the National Medical Products Administration for its self-developed long-acting bispecific antibody QX027N, aimed at treating asthma and atopic dermatitis, marking a significant step in its innovative dual antibody matrix in the field of autoimmune and allergic diseases [1] Group 1 - The candidate drug QX027N represents an important achievement in the company's bispecific antibody research and signifies further progress in its collaborative layout in respiratory and dermatological disease areas [1] - The clinical approval addresses the urgent clinical needs of millions of asthma and atopic dermatitis patients worldwide, indicating the company's commitment to advancing innovative therapies [1] - The company aims to provide more efficient, safer, and more convenient treatment options for patients through continuous development and clinical translation of innovative therapies [1]

Core Viewpoint - The company has received clinical trial approval for its long-acting bispecific antibody QX027N, which is intended for the treatment of asthma and atopic dermatitis, marking a significant advancement in its innovative dual antibody matrix in the field of autoimmune and allergic diseases [1] Group 1 - The National Medical Products Administration has granted clinical trial implicit approval for QX027N, with acceptance numbers CXSL2500757 and CXSL2500758 [1] - QX027N represents a key achievement in the company's bispecific antibody research and signifies further progress in its strategic focus on respiratory and dermatological diseases [1] - The company aims to address the clinical needs of hundreds of millions of asthma and atopic dermatitis patients globally by advancing innovative therapies for more effective, safer, and more convenient treatment options [1]